ATE240959T1 - Chromeno(4,3,2-de)isochinoline als wirksame dopaminrezeptor-liganden - Google Patents

Chromeno(4,3,2-de)isochinoline als wirksame dopaminrezeptor-liganden

Info

Publication number
ATE240959T1
ATE240959T1 AT00942943T AT00942943T ATE240959T1 AT E240959 T1 ATE240959 T1 AT E240959T1 AT 00942943 T AT00942943 T AT 00942943T AT 00942943 T AT00942943 T AT 00942943T AT E240959 T1 ATE240959 T1 AT E240959T1
Authority
AT
Austria
Prior art keywords
improving
treating
compounds
dopamine receptor
receptor ligands
Prior art date
Application number
AT00942943T
Other languages
English (en)
Inventor
David E Nichols
Russell A Grubbs
Richard B Mailman
Original Assignee
Purdue Research Foundation
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Univ North Carolina filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ATE240959T1 publication Critical patent/ATE240959T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Silicon Compounds (AREA)
AT00942943T 1999-06-21 2000-06-20 Chromeno(4,3,2-de)isochinoline als wirksame dopaminrezeptor-liganden ATE240959T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14016699P 1999-06-21 1999-06-21
PCT/US2000/016857 WO2000078765A2 (en) 1999-06-21 2000-06-20 CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS

Publications (1)

Publication Number Publication Date
ATE240959T1 true ATE240959T1 (de) 2003-06-15

Family

ID=22490027

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942943T ATE240959T1 (de) 1999-06-21 2000-06-20 Chromeno(4,3,2-de)isochinoline als wirksame dopaminrezeptor-liganden

Country Status (16)

Country Link
US (2) US6413977B1 (de)
EP (1) EP1192161B1 (de)
JP (1) JP2003502428A (de)
KR (1) KR20020010716A (de)
AT (1) ATE240959T1 (de)
AU (2) AU4536599A (de)
BR (1) BR0011711A (de)
CA (1) CA2373497A1 (de)
DE (1) DE60002867T2 (de)
DK (1) DK1192161T3 (de)
ES (1) ES2199837T3 (de)
MX (1) MXPA01013229A (de)
NO (1) NO20016255L (de)
NZ (1) NZ515613A (de)
PT (1) PT1192161E (de)
WO (1) WO2000078765A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644742A2 (de) * 2003-03-17 2006-04-12 Bayer HealthCare AG Diagnose und therapie von erkrankungen, die mit dem dopamin rezeptor d1a assoziiert sind
AU2004308413A1 (en) * 2003-12-23 2005-07-14 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
NZ570606A (en) * 2006-02-21 2011-11-25 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
US9359303B2 (en) 2009-04-21 2016-06-07 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK297275A (da) * 1974-08-07 1976-02-08 Aspro Nicholas Ltd Isoquinolinderivater
IE53161B1 (en) * 1981-06-18 1988-08-03 Univ Northeastern Orally effective aporphine compounds
US5635506A (en) * 1990-06-26 1997-06-03 Research Corporation Technologies, Inc. 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same

Also Published As

Publication number Publication date
ES2199837T3 (es) 2004-03-01
NO20016255D0 (no) 2001-12-20
WO2000078765A3 (en) 2001-06-28
NZ515613A (en) 2004-03-26
KR20020010716A (ko) 2002-02-04
US6413977B1 (en) 2002-07-02
US6916832B2 (en) 2005-07-12
NO20016255L (no) 2001-12-20
PT1192161E (pt) 2003-09-30
MXPA01013229A (es) 2002-11-04
EP1192161B1 (de) 2003-05-21
US20050080266A1 (en) 2005-04-14
JP2003502428A (ja) 2003-01-21
DE60002867T2 (de) 2004-02-26
DK1192161T3 (da) 2003-08-25
AU4536599A (en) 2001-01-09
DE60002867D1 (de) 2003-06-26
CA2373497A1 (en) 2000-12-28
EP1192161A2 (de) 2002-04-03
AU777522C (en) 2005-07-28
BR0011711A (pt) 2002-03-26
WO2000078765A2 (en) 2000-12-28
AU777522B2 (en) 2004-10-21
AU5749200A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
DE69307340D1 (de) Chinuclidin derivat als substanz p antagonist
MXPA02008770A (es) Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
DE60018274D1 (de) Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
MY107157A (en) Quinuclidine derivatives.
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2432085A1 (en) Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
EA200300854A1 (ru) Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств
TR199902291T2 (xx) �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
NO152902C (no) Analogifremgangsmaae for fremstilling av terapeutisk virksomme 1-alkyl-2-aminotetralinderivater
TNSN99177A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
AP2002002420A0 (en) Fused pyrrolecarboxamides: gaba brain receptor ligands.
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
ATE240959T1 (de) Chromeno(4,3,2-de)isochinoline als wirksame dopaminrezeptor-liganden
DE69822300D1 (de) 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
ATE221067T1 (de) Pyrido(2,3-b)(1,4)benzodiazepinone als m2- rezeptorligand zur behandlung neurologischer störungen
KR960703912A (ko) 중추신경계 활성을 갖는 헤테로사이클 아민(heterocyclic amines having central nervous system activity)
BR0208241A (pt) Composto, composições farmacêutica métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção, ou demência de alzheimer, para aumentar a potência de um efeito terapêutico de um agente do cns, para determinar a presença ou ausência de receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, e, uso de um composto
WO1996032944B1 (en) Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
EP1248641A4 (de) Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
PT1025101E (pt) Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
CA2615856A1 (en) Use of dopamine d2/d3 receptor agonists to treat fibromyalgia
TNSN00178A1 (en) Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1192161

Country of ref document: EP

REN Ceased due to non-payment of the annual fee